BIOMARKER:

FGFR2 mutation

A1 | Sensitive

B | Sensitive

C1 | Sensitive

C2 | Sensitive

C3 | Sensitive

D | Sensitive

A1 | Resistant

B | Resistant

C1 | Resistant

C2 | Resistant

C3 | Resistant

D | Resistant

Cholangiocarcinoma

Solid Tumor

Melanoma

Non Small Cell Lung Cancer

Gastric Cancer

Urothelial Cancer

Bladder Cancer

Endometrial Cancer

Estrogen Receptor Positive Breast Cancer

Multiple Myeloma

erdafitinib

FGFR2 mutation|Cholangiocarcinoma|erdafitinib

FGFR2 mutation|Solid Tumor|erdafitinib

FGFR2 mutation|Gastric Cancer|erdafitinib

FGFR2 mutation|Bladder Cancer|erdafitinib

FGFR2 mutation|Urothelial Cancer|erdafitinib

KIN-3248

FGFR2 mutation|Cholangiocarcinoma|KIN-3248

FGFR2 mutation|Gastric Cancer|KIN-3248

futibatinib

FGFR2 mutation|Cholangiocarcinoma|futibatinib

FGFR2 mutation|Solid Tumor|futibatinib

TT-00420

FGFR2 mutation|Cholangiocarcinoma|TT-00420

FGFR2 mutation|Solid Tumor|TT-00420

ARQ 087

FGFR2 mutation|Cholangiocarcinoma|ARQ 087

nintedanib

FGFR2 mutation|Non Small Cell Lung Cancer|nintedanib

pemigatinib

FGFR2 mutation|Cholangiocarcinoma|pemigatinib

Debio 1347

FGFR2 mutation|Cholangiocarcinoma|Debio 1347

infigratinib

FGFR2 mutation|Cholangiocarcinoma|infigratinib

FGFR2 mutation|Endometrial Cancer|infigratinib

FGFR2 mutation|Multiple Myeloma|infigratinib

PD173074

FGFR2 mutation|Endometrial Cancer|PD173074

TKI258

FGFR2 mutation|Endometrial Cancer|TKI258

CPL304110

FGFR2 mutation|Solid Tumor|CPL304110

fulvestrant

FGFR2 mutation|Estrogen Receptor Positive Breast Cancer|fulvestrant

palbociclib

FGFR2 mutation|Estrogen Receptor Positive Breast Cancer|palbociclib

eFT226

FGFR2 mutation|Solid Tumor|eFT226

CTLA4 inhibitor

FGFR2 mutation|Melanoma|CTLA4 inhibitor

Immunotherapy

FGFR2 mutation|Non Small Cell Lung Cancer|Immunotherapy

FGFR2 mutation|Urothelial Cancer|Immunotherapy

FGFR2 inhibitor

FGFR2 mutation|Cholangiocarcinoma|FGFR2 inhibitor

PD1 inhibitor

FGFR2 mutation|Melanoma|PD1 inhibitor

PD-L1 inhibitor

FGFR2 mutation|Melanoma|PD-L1 inhibitor